HOME >> MEDICINE >> NEWS
Studies suggest investigational agent reduces disease activity in MS

BOSTON A new drug under investigation shows a reduction in disease activity in multiple sclerosis (MS), according to two studies that will be presented at the American Academy of Neurology's 59th Annual Meeting in Boston, April 28 May 5, 2007. The drug reduced disease activity as indicated by MRI scans.

Both of the studies involved people with the relapsing-remitting form of MS, where symptoms flare up and then subside. By 24 weeks, treatment with the drug rituximab reduced the number of areas of brain damage, or lesions, in people with MS and the number of relapses, or times when symptoms flare up, when compared with placebo.

Rituximab is a therapeutic antibody that selectively targets and depletes a subset of immune cells called B-cells by targeting a specific protein on their surface.

"This is the first drug to target B-cells and may represent a potential new treatment strategy for relapsing-remitting MS," said study author Stephen Hauser, MD, of the University of California, San Francisco, and a member of the American Academy of Neurology. "While these are early stage clinical trials, these results are exciting, because the current drugs available for MS are only partially effective in reducing disease activity and preventing exacerbations. New and more effective treatments for MS are sorely needed, especially for people who do not adequately respond to currently available medications. These data are also important because they demonstrate that B-cells, which are the precursors of antibody-producing cells, play an essential role in mediating relapses of MS."

In the first study, a randomized, placebo-controlled trial, 69 people were given two infusions of rituximab two weeks apart and 35 were given a placebo. The participants were followed for six months. Those given rituximab had approximately 90 percent fewer brain lesions than those given placebo. During the six-month period, 58 percent fewer of those taking the d
'"/>

Contact: Angela Babb
ababb@aan.com
651-695-2789
American Academy of Neurology
1-May-2007


Page: 1 2 3

Related medicine news :

1. Studies show antidepressants not linked to birth defects
2. Studies show role of age, gender, race and weight on cancer risk and treatment
3. Studies highlight advances in diagnosis, medical therapy
4. Studies highlight real world use, safety of drug-eluting stents
5. Studies led by Rhode Island Hospital confirm safety and efficacy
6. Studies identify food sources of disease and drug resistance
7. Studies provide new evidence on risks associated with Cox-2 inhibitors and NSAIDs
8. Studies highlight need to monitor heart function in breast cancer patients
9. Studies examine physician disclosure of medical errors
10. Studies indicate medication can be an effective therapy for smoking cessation
11. Studies evaluating health effects of dental amalgam fillings in children confirm safety

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/17/2017)... City, Utah (PRWEB) , ... August 17, 2017 , ... ... share how to efficiently and effectively grow a dental practice in a competitive market ... hours of dental C.E. that could just transform you and your practice.” says Daniel ...
(Date:8/17/2017)... ... August 17, 2017 , ... Recently voted Houston’s ... by being among Houston’s first plastic surgeons to offer boutique and concierge services. ... without disrupting busy schedules and maintaining the utmost discretion in the comfort of ...
(Date:8/17/2017)... ... August 17, 2017 , ... Florida Hospital ... 16, to community partners. The newly renovated ER was designed with patients in ... emergencies, eight semi-private rooms to deliver patient results, improve efficiencies and reduce length ...
(Date:8/17/2017)... ... August 17, 2017 , ... With the introduction of new devices, new ... of changes to the smartwatch market. As of June 2017, nearly nine percent of ... six months prior. Additionally, according to latest WEAR Report Industry Overview and Forecast from ...
(Date:8/17/2017)... ... August 17, 2017 , ... Pot Valet is a leading provider of premium ... in the state, and soon, every state in the country, the company offers patients ... cannabis dispensary altogether. , According to Pot Valet, all California patients have ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... CaryRx, a next-generation full-service pharmacy, has announced the launch of ... Washington D.C. metropolitan area. CaryRx aims ... medications through the convenience of its patient-friendly mobile app. Prescriptions ... hour to any location in D.C. ... to Washington D.C. ," says Areo Nazari ...
(Date:7/31/2017)... 7D Surgical, developer of ground breaking surgical navigation technologies, announced ... to support its strategic sales plan in Maryland ... 7D Surgical has entered into an exclusive sales representative agreement ... within those markets. ... Spartan Medical Purchases 7D Surgical ...
(Date:7/27/2017)... Pa., July 27, 2017  West Pharmaceutical Services, Inc. ... results for the second-quarter 2017 and updated financial guidance ... Second-Quarter 2017 Highlights Reported net ... over the prior-year quarter. Net sales at constant currency ... reported-diluted EPS was $0.51, compared to $0.60 in the ...
Breaking Medicine Technology:
Cached News: